Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Variants & evidence
1,187 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FLT3 Y572del5 | ||||||||
| Midostaurin | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID12859Ba/F3 cell lines expressing the variant FLT3 Y572del showed sensitivity to midostaurin and was 5 to 10-fold more sensitive than the FLT3-ITD construct. PMID 33914060 · Young et al., 2021 · Open in CIViC | civic |
| Crenolanib + Lestaurtinib + Midostaurin + Ponatinib + Quizartinib + SorafenibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 5 | submitted | EID9306The construct supported IL-3 independent growth of Ba/F3 cells. It showed FLT-3 autophosphorylation and downstream signaling via STAT5, AKT, and ERK1/2 pathways. With IL-3 deprivation, the cells showe… (full text at CIViC) PMID 33914060 · Young et al., 2021 · Open in CIViC | civic |
| Ponatinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID12864Ba/F3 cell lines expressing the variant FLT3 Y572del showed sensitivity to ponatinib comparable to the FLT3-ITD construct (Figure 4). PMID 33914060 · Young et al., 2021 · Open in CIViC | civic |
| Quizartinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID12860Ba/F3 cell lines expressing the variant FLT3 Y572del showed sensitivity to quizartinib comparable to the FLT3-ITD construct. PMID 33914060 · Young et al., 2021 · Open in CIViC | civic |
| Sorafenib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | submitted | EID12862Ba/F3 cell lines expressing the variant FLT3 Y572del showed sensitivity to sorafenib comparable to the FLT3-ITD construct (Figure 4). PMID 33914060 · Young et al., 2021 · Open in CIViC | civic |
| FLT3 Y589D1 | ||||||||
| (predisposing) | Acute Myeloid LeukemiaCURATED_BROADER | Predisposing | C | N/A N/A | 1 | submitted | EID8928Single strand polymorphism targeting FLT3 in addition to RUNX1, KIT, CEBPA, PTPN11, and NRAS was carried out to identify novel recurring gene mutations in an acute myeloid leukemia cohort comprised of… (full text at CIViC) PMID 15667533 · Smith et al., 2005 · Open in CIViC | civic |
| FLT3 Y591_V592INSVDFREYE4 | ||||||||
| Palbociclib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | submitted | EID4734In an in vitro study, MOLM-14, PL21 and MV4-11 cell lines expressing FLT3 internal tandem duplication mutation (FLT3-ITD) demonstrated increased sensitivity to palbociclib treatment, compared to THP-1… (full text at CIViC) PMID 27099147 · Uras et al., 2016 · Open in CIViC | civic |
| Sunitinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | C | Supports Sensitivity Response | — | submitted | EID4731In a retrospective study of 15 acute myeloid leukemia patients, the patients with FLT3 internal tandem duplication mutation (n=2) were associated with improved response to sunitinib treatment. The pat… (full text at CIViC) PMID 15459012 · Fiedler et al., 2005 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | |||||||
| FLT3 Y6931 | ||||||||
| Gilteritinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | submitted | EID8285With vitro proliferation assay in Ba/F3 cells, it was found that the cells bearing FLT3-ITD Y693C/N exhibited >10-fold resistance to Gilteritinib. Similar resistance was found in cells bearing FLT3-IT… (full text at CIViC) PMID 32040554 · Tarver et al., 2020 · Open in CIViC | civic |
| FLT3 Y842C7 | ||||||||
| FLT3/ABL/Aurora Kinase Inhibitor KW-2449 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID8336The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib a… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC | civic |
| Lestaurtinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID8339A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/IT… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC | civic |
| Midostaurin | Acute Myeloid Leukemia | |||||||
| FLT3 Y842H1 | ||||||||
| (predisposing) | Acute Myeloid LeukemiaCURATED_BROADER | Predisposing | C | N/A N/A | 1 | submitted | EID8929Single strand polymorphism targeting FLT3 in addition to RUNX1, KIT, CEBPA, PTPN11, and NRAS was carried out to identify novel recurring gene mutations in an acute myeloid leukemia cohort comprised of… (full text at CIViC) PMID 15667533 · Smith et al., 2005 · Open in CIViC | civic |
| ERG Fusion3 | ||||||||
| (diagnostic) | Acute Myeloid Leukemia with FUS-ERGALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12321This study investigates the diagnostic importance of the translocation t(16;21)(p11;q22), resulting in the TLS/FUS::ERG fusion gene, in acute myeloid leukemia (AML). The authors utilized RT-PCR to det… (full text at CIViC) PMID 9242552 · Kong et al., 1997 · Open in CIViC | civic |
| 〃 | Acute Myeloid Leukemia with FUS-ERGALIAS | Diagnostic | B | Supports Positive | 4 | accepted | EID12322This international retrospective study investigates the diagnostic features of acute myeloid leukemia (AML) with the t(16;21) translocation resulting in the FUS::ERG fusion gene in pediatric patients.… (full text at CIViC) PMID 30150206 · Noort et al., 2018 · Open in CIViC | civic |
| 〃 | Acute Myeloid Leukemia with FUS-ERG | |||||||
| GATA1 Mutation1 | ||||||||
| (diagnostic) | Myeloid Leukemia Associated with Down Syndrome | Diagnostic | A | Supports Positive | 5 | submitted | EID8511Children with Down syndrome are at increased risk to developing Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia associated with Down Syndrome (ML-DS). GATA1, a gene that encodes an essentia… (full text at CIViC) PMID 27069254 · Arber et al., 2016 · Open in CIViC | civic |
| GATA1 p.Ser51Alafs*861 | ||||||||
| (prognostic) | Transient Abnormal MyelopoiesisALIAS | Prognostic | C | Supports Better Outcome | 2 | submitted | EID8302We report an additional case of twin-to-twin transmission of a TAM clone with identical GATA1 exon 2 mutations in monochorionic-diamniotic twin infants without constitutional T21. This case along with… (full text at CIViC) PMID 32464589 · Roseman et al., 2020 · Open in CIViC | civic |
| GATA2 Mutation1 | ||||||||
| (prognostic) | Acute Myeloid LeukemiaCURATED_BROADER | Prognostic | B | Supports Better Outcome | 3 | submitted | EID8343GATA2 ZF1 mutations are associated with distinct clinico-biological features and predict better prognosis, different from zinc finger 1 mutations, in AML patients. ZF1 mutations were closely associate… (full text at CIViC) PMID 30190467 · Tien et al., 2018 · Open in CIViC | civic |
| IDH1 Mutation3 | ||||||||
| Ivosidenib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 3 | accepted | EID7278I phase 1 trial for patients with IDH1-mutated AML, patients who received ivosidenib (AG-120). The rate of complete remission was 21.6%, the over all response rate was 30.4%. PMID 29860938 · DiNardo et al., 2018 · Open in CIViC | civic |
| Azacitidine + IvosidenibCombination | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 5 | submitted | EID10313Phase 3 trial of 146 patients randomized to either IDH1 inhibitor ivosidenib and azacitidine or azacitidine and placebo revealed significantly longer event-free survival in the ivosidenib-group. Patie… (full text at CIViC) PMID 35443108 · Montesinos et al., 2022 · Open in CIViC | civic |
| Venetoclax | Acute Myeloid Leukemia | |||||||
| IDH1 R13214 | ||||||||
| (prognostic) | Myelodysplastic SyndromeCURATED_BROADER | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID374IDH1 R132 mutation in patients suffering from myelodysplastic syndromes is associated with worse overall survival. PMID 20494930 · Thol et al., 2010 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Prognostic | B | Does Not Support N/A | 3 | accepted | EID160Mutation status of IDH1 did not change event-free survival of patients with an NPM1 mutation. PMID 20805365 · Schnittger et al., 2010 · Open in CIViC | civic |
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | B | Supports Oncogenicity | ||||
| IDH1 R132 + IDH1 R132L1 | ||||||||
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | B | Supports Oncogenicity | 3 | submitted | EID12898In the phase 3 AGILE trial enrolling patients with newly diagnosed IDH1-mutated AML who were ineligible for intensive induction chemotherapy, IDH1 R132 mutations (confirmed by FDA-approved Abbott Real… (full text at CIViC) PMID 35443108 · Montesinos et al., 2022 · Open in CIViC | civic |
| IDH1 R132C5 | ||||||||
| (diagnostic) | Acute Myeloid LeukemiaCURATED_BROADER | Diagnostic | B | Supports Positive | 3 | accepted | EID224IDH1 R132 mutation is associated with patients of older age, high platelet count during diagnosis, cytogenic normalcy and NPM1 mutation. PMID 20538800 · Abbas et al., 2010 · Open in CIViC | civic |
| (prognostic) | Acute Myeloid LeukemiaCURATED_BROADER | Prognostic | B | Does Not Support N/A | 2 | accepted | EID324IDH1 R132 mutation in patients with AML is not associated with any prognostic value compared to patients with wild-type IDH1. PMID 20538800 · Abbas et al., 2010 · Open in CIViC | civic |
| BPTES | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | ||||
| IDH1 R132C + IDH1 R132H2 | ||||||||
| (oncogenic) | Acute Myeloid LeukemiaCURATED_BROADER | Oncogenic | B | Supports Oncogenicity | 3 | submitted | EID12902Popovici-Muller et al. report that IDH1 R132 mutations are gain-of-function alterations that result in production of the oncometabolite D-2-hydroxyglutarate (2-HG). The authors state that elevated 2-H… (full text at CIViC) PMID 29670690 · Popovici-Muller et al., 2018 · Open in CIViC | civic |
| Ivosidenib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID12903Popovici-Muller et al. reported preliminary efficacy data from an ongoing phase 1 study of ivosidenib (AG-120) monotherapy in patients with IDH1-mutated malignancies. In patients with relapsed or refr… (full text at CIViC) PMID 29670690 · Popovici-Muller et al., 2018 · Open in CIViC | civic |
Data updated 1 hour agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.
| Predictive |
| C |
| Supports Sensitivity Response |
| — |
| submitted |
EID4732In a phase I study of 29 acute myeloid leukemia patients, patients with FLT3 internal tandem duplication (ITD) mutation (n=3) were associated with improved response to sunitinib monotherapy compared … (full text at CIViC) PMID 14654525 · O'Farrell et al., 2003 · Open in CIViC |
| civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | — | submitted | EID4733In an in vitro study, leukemia M4;11 (endogenous), myeloid 32D (overexpression) and Chinese hamster ovary (transient expression) cell lines expressing FLT3 internal tandem duplication mutation demonst… (full text at CIViC) PMID 12531805 · O'Farrell et al., 2003 · Open in CIViC | civic |
| Predictive |
| D |
| Supports Sensitivity Response |
| 3 |
| accepted |
EID8340A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/IT… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC |
| civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID8934A novel mutation (FLT3 Y842C) was detected in 2 AML patients (n = 110). Ex vivo PKC412 treatment of primary blasts resulted in suppression of constitutive FLT3 and STAT-5 activation (Figure 1D). Cell … (full text at CIViC) PMID 15345593 · Kindler et al., 2005 · Open in CIViC | civic |
| Quizartinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID8654A screen using saturation mutagenesis of FLT3/ITD followed by selection of transfected TF1 cells in FLT3 TKIs identified Y842C. Cytotoxicity assessed by MTT demonstrated Ba/F3 cells expressing FLT3/IT… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC | civic |
| Sorafenib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 4 | accepted | EID8337The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib a… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC | civic |
| Sunitinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Resistance | 3 | accepted | EID8338The authors used saturation mutagenesis of FLT3/ITD followed by selection of transfected cells in FLT3 TKI. The FLT3/ITD Y842C mutation produced high-level resistance to KW2449, sorafenib, sunitinib a… (full text at CIViC) PMID 22858906 · Williams et al., 2013 · Open in CIViC | civic |
| Diagnostic |
| C |
| Supports Positive |
| 3 |
| accepted |
EID12323This study focuses on the diagnostic characteristics of pediatric patients with the t(16;21)(p11;q22)/FUS::ERG translocation using advanced molecular methods. The authors studied four cases of pediatr… (full text at CIViC) PMID 29427188 · Zerkalenkova et al., 2018 · Open in CIViC |
| civic |
| Predictive |
| C |
| Supports Sensitivity Response |
| 3 |
| accepted |
EID8856In this case series, 7 elderly patients with secondary AML (sAML) not eligible for intensive chemotherapy and refractory to HMA (including 1 patient with antecedent myeloproliferative neoplasm) were t… (full text at CIViC) PMID 30725494 · Huemer et al., 2019 · Open in CIViC |
| civic |
| 3 |
| submitted |
EID12900In this post hoc long-term follow-up of the phase 3 AGILE trial (NCT03173248; median follow-up 28.6 months; n=148), IDH1 R132 mutations served as the obligate driver alteration defining patient eligib… (full text at CIViC) PMID 40706052 · Montesinos et al., 2025 · Open in CIViC |
| civic |
| (diagnostic) | Acute Myeloid LeukemiaCURATED_BROADER | Diagnostic | B | Supports Positive | 2 | accepted | EID223In leukemia patients, IDH1 R132 mutation is associated with adults and normal karyotype. PMID 20376086 · Ho et al., 2010 · Open in CIViC | civic |
| (prognostic) | Acute Myeloid LeukemiaCURATED_BROADER | Prognostic | B | Does Not Support N/A | 2 | accepted | EID323The complete remission and overall survival rates in patients with IDH1 R132 mutation is not significantly different from those who do not have this mutation. PMID 20368538 · Wagner et al., 2010 · Open in CIViC | civic |
| (predisposing) | Acute Myeloid LeukemiaCURATED_BROADER | Predisposing | C | Does Not Support Likely Pathogenic | 3 | submitted | EID7637Out of 520 patient samples analyzed, 9.6% (n=50) had an IDH1 mutation. Of the patients with an IDH1 mutation, 44% (n=22) had a heterozygous R132H mutation, 42% (n=21) had a R132C mutation, 12% (n=6) h… (full text at CIViC) PMID 20625116 · Boissel et al., 2010 · Open in CIViC | civic |
| Ivosidenib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID13077In a multicenter phase I study, 33 patients with newly diagnosed IDH1 R132-mutated acute myeloid leukemia who were ineligible for standard therapy received ivosidenib 500 mg once daily. The CR+CRh rat… (full text at CIViC) PMID 31841594 · Roboz et al., 2020 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13076In a subgroup analysis of a multicenter phase I study, 17 patients with relapsed or refractory IDH1 R132-mutated acute myeloid leukemia who responded to ivosidenib 500 mg once daily subsequently under… (full text at CIViC) PMID 33772143 · DiNardo et al., 2021 · Open in CIViC | civic |
| 〃 | Myelodysplastic SyndromeCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13287In the relapsed or refractory myelodysplastic syndrome (MDS) substudy of the phase 1, open-label, single-arm, multinational first-in-human trial of ivosidenib (NCT02074839), adults with MDS carrying a… (full text at CIViC) PMID 38640348 · DiNardo et al., 2024 · Open in CIViC | civic |
| Azacitidine + IvosidenibCombination | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 5 | submitted | EID12899In the double-blind, placebo-controlled, phase III AGILE trial (NCT03173248), 146 patients with newly diagnosed IDH1-mutated acute myeloid leukemia (AML) who were ineligible for intensive induction ch… (full text at CIViC) PMID 35443108 · Montesinos et al., 2022 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 5 | submitted | EID12901This post hoc long-term follow-up analysis of the phase 3, double-blind, placebo-controlled AGILE trial (NCT03173248) reports updated outcomes for 148 patients with newly diagnosed IDH1-mutated AML in… (full text at CIViC) PMID 40706052 · Montesinos et al., 2025 · Open in CIViC | civic |
| Olutasidenib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID13078In a preplanned interim analysis of the pivotal phase 2 cohort of an open-label, multicenter phase 1/2 trial, 153 patients with relapsed or refractory IDH1 R132-mutated acute myeloid leukemia received… (full text at CIViC) PMID 36724515 · de Botton et al., 2023 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13080In a multicenter, open-label phase 1 study, 22 response-evaluable patients with relapsed or refractory IDH1-mutated acute myeloid leukemia received olutasidenib monotherapy. Nine patients achieved an … (full text at CIViC) PMID 36370742 · Watts et al., 2023 · Open in CIViC | civic |
| 〃 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 3 | submitted | EID13091In a phase 2 subgroup analysis of patients with IDH1 R132-mutated acute myeloid leukemia (AML) previously treated with venetoclax-based therapy, 16 patients received olutasidenib monotherapy at 150 mg… (full text at CIViC) PMID 38538632 · Cortes et al., 2024 · Open in CIViC | civic |
| 3 |
| accepted |
EID2332In an experimental study of acute myeloid leukemia (AML) cell lines expressing IDH1 R132C, IDH1 R132G, or IDH1 R132H mutations were associated with increased sensitivity to small molecule glutaminase … (full text at CIViC) PMID 24333121 · Emadi et al., 2014 · Open in CIViC |
| civic |
| GSK321 | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID732Newly developed allosteric inhibitors (GSK321) of IDH1 led to granulocytic differentiation in-vitro and in-vivo. PMID 26436839 · Okoye-Okafor et al., 2015 · Open in CIViC | civic |
| Ivosidenib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID2331In a clinical study of 17 relapsed or refractory AML patients harboring IDH1 mutations, these patients were associated with response to AG-120 monotherapy; 4/7 patients who achieved a response experie… (full text at CIViC) PMID 25583779 · 2015 · Open in CIViC | civic |